Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.80 |
| ▸ | CDK4 | P11802 | 16/20 | 0.74 |
| ▸ | CDK1 | P06493 | 4/20 | 0.74 |
| ▸ | CCND3 | P30281 | 3/20 | 0.74 |
| ▸ | GAK | O14976 | 1/20 | 0.74 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.74 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.74 |
| ▸ | FECH | P22830 | 1/20 | 0.74 |
| ▸ | CCND1 | P24385 | 1/20 | 0.74 |
| ▸ | CDK9 | P50750 | 1/20 | 0.74 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.74 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.74 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.74 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.74 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.74 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.74 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.74 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29639522 | 1.00 | CDK2 (0.80) | CDK2CDK4CDK1CCND3GAK | |
| SCHEMBL1992896 | 0.98 | CDK2 (0.78) | CDK2CDK4CDK1CCND3GAK | |
| SCHEMBL26641432 | 0.96 | CDK2 (0.75) | CDK2CDK4CDK1CCND3GAK | |
| SCHEMBL15153216 | 0.96 | CDK2 (0.74) | CDK2CDK4CDK1CCND3GAK | |
| SCHEMBL28619136 | 0.95 | CDK4 (0.74) | CDK2CDK4CDK1CCND3GAK | |
| SCHEMBL15153191 | 0.95 | CDK2 (0.72) | CDK2CDK4CDK1CCND3GAK | |
| SCHEMBL31727518 | 0.94 | CDK2 (0.72) | CDK2CDK4CDK1CCND3GAK | |
| SCHEMBL28620311 | 0.94 | CDK4 (0.76) | CDK2CDK4CDK1CCND3GAK | |
| SCHEMBL30643564 | 0.93 | CDK4 (0.80) | CDK2CDK4CDK1CCND3GAK | |
| SCHEMBL31728206 | 0.92 | CDK4 (0.77) | CDK2CDK4CDK1CCND3GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210122754-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB SUCCINATE AND ITS NOVEL CRYSTALLINE FORMS THEREOF | NATCO PHARMA LTD (IN) | 2021-04-29 | — | — | US | claimed |
| WO-2019142206-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB SUCCINATE AND ITS NOVEL CRYSTALLINE FORMS THEREOF | NATCO PHARMA LIMITED (IN) | 2019-07-25 | — | — | WO | claimed |
| EP-4313987-B1 | PROCESS FOR THE PREPARATION OF RIBOCICLIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRKA D D NOVO MESTO (SI) | 2026-01-14 | — | — | EP | disclosed |
| EP-4626890-A1 | RIBOCICLIB SALTS AND FORMULATIONS THEREOF | KRKA, d.d., Novo mesto (SI) | 2025-10-08 | — | — | EP | disclosed |
| US-12421227-B2 | Ribociclib salts and solid state forms thereof | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2025-09-23 | — | — | US | disclosed |
| WO-2024115680-A1 | RIBOCICLIB SALTS AND FORMULATIONS THEREOF | KRKA, D.D., NOVO MESTO (SI) | 2024-06-06 | — | — | WO | disclosed |
| EP-4327880-A2 | SOLID STATE FORM OF RIBOCICLIB SUCCINATE | Assia Chemical Industries Ltd (IL) | 2024-02-28 | — | — | EP | disclosed |
| EP-4313987-A2 | PROCESS FOR THE PREPARATION OF RIBOCICLIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRKA, d.d., Novo mesto (SI) | 2024-02-07 | — | — | EP | disclosed |
| EP-3672968-B1 | SOLID STATE FORM OF RIBOCICLIB SUCCINATE | ASSIA CHEM IND LTD (IL) | 2023-11-01 | — | — | EP | disclosed |
| CN-111386272-B | Improved preparation method of Riboxib and salt thereof | 费森尤斯卡比肿瘤学有限公司 | 2023-01-06 | — | — | CN | disclosed |
| US-11440912-B2 | Process for the preparation of ribociclib and its salts | FRESENIUS KABI ONCOLOGY LTD (IN) | 2022-09-13 | — | — | US | disclosed |
| US-8957074-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| US-20130217698-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | ASTEX THERAPEUTICS LTD (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20130217698-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | ASTEX THERAPEUTICS LTD (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| EP-2536730-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | Novartis AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| WO-2012064805-A1 | SALT(S) OF 7-CYCLOPENTYL-2 -(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | NOVARTIS AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115878-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | CALIENNI JOHN VINCENT (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115878-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | CALIENNI JOHN VINCENT (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440912-B2 | Process for the preparation of ribociclib and its salts | SUCLG2, IDH1, RRM2B | CDK2 138/4885CDK4 75/4885CDK1 837/4885 |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | CDK2 9/4885CDK4 1/4885CDK1 11/4885 |
| US-20130217698-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | PKD2, SLC6A7, DHPS | CDK2 2620/4885CDK4 2373/4885CDK1 4131/4885 |
| US-12421227-B2 | Ribociclib salts and solid state forms thereof | RTCB, KRAS, RRM2B | CDK2 25/4885CDK4 11/4885CDK1 231/4885 |
| US-20120115878-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | PKD2, SLC6A7, DHPS | CDK2 2620/4885CDK4 2373/4885CDK1 4131/4885 |
| US-20210122754-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB SUCCINATE AND ITS NOVEL CRYSTALLINE FORMS THEREOF | RRM2B, CPS1, RRBP1 | CDK2 34/4885CDK4 111/4885CDK1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.